Laboratorio de Inmunobiología y Diagnóstico Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero.
Laboratorio de Anticuerpos Monoclonales, Unidad de Desarrollo Tecnológico e Investigación Molecular, Instituto de Diagnóstico y Referencia Epidemiológico Dr. Manuel Martínez Báez (InDRE), Mexico City, Mexico.
Bol Med Hosp Infant Mex. 2023;80(3):153-164. doi: 10.24875/BMHIM.23000123.
Immunotherapy is one of the most innovative treatments in the current field of oncology and consists of stimulating the immune system to eliminate tumoral cells. Monoclonal antibodies (mAbs) are glycoproteins secreted by B-cells capable of recognizing and neutralizing foreign organisms or antigens. Structurally, they are composed of two heavy and two light chains. The generation of therapeutic mAbs is one of the most developed and fastest-growing areas of the biotechnological and pharmaceutical industries and is an important adjunct to cancer therapy. Several antibodies have been approved for human administration and can be mouse-derived, chimeric, humanized, or fully human. mAbs main mechanism of action includes the lysis of the tumoral cells through inducing apoptosis, phagocytosis, complement activation, or signaling inhibition.
免疫疗法是当前肿瘤学领域中最具创新性的治疗方法之一，它旨在通过刺激免疫系统来消除肿瘤细胞。单克隆抗体（mAbs）是 B 细胞分泌的糖蛋白，能够识别和中和外来生物或抗原。从结构上看，它们由两条重链和两条轻链组成。治疗性 mAbs 的产生是生物技术和制药行业发展最快、最发达的领域之一，是癌症治疗的重要辅助手段。已经有几种抗体被批准用于人体，并可以是鼠源性、嵌合性、人源化或全人源的。mAbs 的主要作用机制包括通过诱导细胞凋亡、吞噬作用、补体激活或信号抑制来裂解肿瘤细胞。
